How NC hospitals dealt with readmission penalties

Penalizing hospitals if patients are readmitted shortly after being discharged has appeared to change facilities' approach to care, according to WUNC’s look at several hospitals in the Triangle region of North Carolina.

“Out of the hospital is a big change for most hospital systems,” said West Paul, MD, PhD, the chief quality officer for WakeMed Health and Hospitals. “It's the right thing to do, and it makes everyone's lives easier.”

WakeMed’s Raleigh hospital saw its penalty reduced to zero for 2018. Its Cary, North Carolina, hospital, however, was given a 0.6 percent penalty, putting it in line with about 63 percent of the hospitals in the state. The highest penalty among the hospitals examined by WUNC was Duke Raleigh, which may be indicative of the issues these penalties present to academic medical centers.

“Some of those local, especially rural, communities may not have the capabilities or sometimes the experience with sicker, more complicated patients,” said Thomas Owens, MD, Duke University Health System’s chief medical officer. “And in those settings if the patient presents to the local emergency room—which is the right thing to do if you are sick and concerned about your care—there's a very high likelihood that you will get readmitted to the hospital. Higher than if you were closer to one of our care facilities.”

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.